Boehringer Ingelheim inks deal for targeted cancer antibodies from Singapore research org

As Boehringer Ingelheim looks to build out its efforts in oncology, its latest deal will turn toward Singapore.

The German pharma announced Thursday that it has signed a global licensing agreement with the Singapore-based Agency for Science, Technology and Research (A*STAR). While specific financial breakdown was not disclosed, Boehringer will pay more than €100 million ($107 million) in upfront cash and milestones, as well as success-based development and commercialization targets.